Effect of Celery (Apium graveolens L.) Microgreens on Drosophila melanogaster
Main Article Content
Abstract
Celery (Apium graveolens L. ; family : Apiaceae) was often used as a spice in daily food. However, this plant contains many antioxidant compounds useful for attenuating neurodegenerative disorders including Parkinson's disease. Planting celery in the form of microgreens harvested 15 days was expected to increase the content of bioactive compounds. In the current study, we intended to evaluate the neuromodulatory potential of methanol extract of celery microgreens on fruit flies (Drosophila melanogaster Meigen : family Drosophilidae ; ordo : Diptera) which were exposed to paraquat. Neuroprotective capacity was assessed by survival rate, locomotor performance, lipid peroxidation and dopamine content after being treated with 120 µg/mL extract of celery microgreens and 3.5 mM paraquat for 4 days. Phytochemical constituents from extract of celery microgreens were measured including total polyphenol content and antioxidant activity using the radicals scavenging method. Exposure of adult fruit flies to paraquat will cause a decrease in the survival and locomotor phenotype improved by extract of celery microgreens treatment. In parallel, increased malondialdehyde content from lipid peroxidation and decreased dopamine content can be improved by the presence of celery microgreens extract. Neuroprotective capacities indicate a high content of antioxidant compounds of celery microgreens extract. Our study concludes that celery microgreens exhibited to retard the effect of oxidative stress that causes Parkinson's disease.
Received 26/2/2020
Revised 20/1/2023
Accepted 22/1/2023
Published Online First 20/4/2023
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Niveditha S, Ramesh SR, Shivanandappa T. Paraquat-induced movement disorder in relation to oxidative stress-mediated neurodegeneration in the brain of Drosophila melanogaster. Neuro Res. 2017; 42: 3310–20. http://doi.org/ 10.1007/s11064-017-2373-y
WHO. Conclusion and recommendations, Neurological Disorders: Public Health Challenges, World Health Organization, (Chapter 4), 2006.
Siddique YH, Jyoti S. Alteration in biochemical parameters in the brain of transgenic Drosophila melanogaster model of Parkinson’s disease exposed to apigenin. Integ Med Res. 2017; 6(3): 245–253. https://doi.org/10.1016/j.imr.2017.04.003
Thakolwiboon S, Julayanont P, Ruthirago D. Pesticides and Parkinson’s disease: A potential hazard in agricultural communities. Southwest Respir. Crit. Care Chron. 2017; 5(20): 60–67. https://doi.org/10.12746/swrccc. v5i20.406
Nagpal I, Abraham SK. Ameliorative effects of gallic acid, quercetin and limonene on urethane-induced genotoxicity and oxidative stress in Drosophila melanogaster. Toxicol Mech Methods. 2017 Feb; (1 – 8). https://doi.org/10.1080/15376516.2016.1278294
Jhonsa DJ, Badgujar LB, Sutariya BK, Saraf MN. Neuroprotective effect of flavonoids against paraquat induced oxidative stress and neurotoxicity in Drosophila melanogaster. Curr Top Nutraceutical Res. 2016; 14 (4): 283-294.
Sanz FJ, Solana-Manrique C, Muñoz-Soriano V, Calap-Quintana P, Moltó MD, Paricio N. Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models. Free Rad Bio Med. 2017 Apr; 108: 683–691. https://doi.org/10.1016/j.freeradbiomed.2017.04.364
Stephano F, Nolte S, Hoffmann J, El-Kholy S, von Frieling J, Bruchhaus I, et al. Impaired Wnt signaling in dopamine containing neurons is associated with pathogenesis in a rotenone triggered Drosophila Parkinson’s disease model. Sci Report. 2018; 8: 2372. https://doi.org/10.1038/s41598-018-20836-w
Yang SY, Gegg M, Chau D, Schapira A. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation. Neurobiol Dis. 2020 Feb; 134 :1-8. https://doi.org/10.1016/j.nbd.2019.104620
Xiong Y, Yu J. Modeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits? Front. Neurol. 2018 Apr; 9 (228): 1-15. https://doi.org/10.3389/fneur.2018.00228
Sakai R, Suzuki M, Ueyama M, Takeuchi T, Minakawa EN, Hayakawa H, et al. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease. PLoS One. 2019 Jun 26; 14(6): e0218261. https://doi.org/10.1371/journal.pone.0218261
Soares J J, Rodrigues DT, Gonçalves MB, Lemos MC, Gallarreta MS, Bianchini MC, et al. Paraquat exposure-induced Parkinson’s disease-like symptoms and oxidative stress in Drosophila melanogaster: Neuroprotective effect of Bougainvillea glabra Choisy, Biomed Pharmacother. 2017; 95: 245–251. https://doi.org/10.1016/j.biopha.2017.08.073
Aryal B, Lee Y. Disease model organism for Parkinson disease: Drosophila melanogaster. BMB Rep. 2019 Nov; 52(4): 250-258. https://doi.org/10.5483/BMBRep.2019.52.4.204
Helena Xicoy H, Peñuelas N, Miquel Vila M, Laguna A. Autophagic- and Lysosomal-Related Biomarkers for Parkinson’s Disease: Lights and Shadows. Cells. 2019 Oct; 8 (1317): 1-20. https://doi.org/10.3390/cells8111317
Xiong Y, Dawson, TM, Dawson VL. Models of LRRK2 associated Parkinson’s disease. Adv Neurobiol. 2017 Jan; 14: 163–191. https://doi.org/10.1007/978-3-319-49969-7_9.
Quintero-Espinosa D, Jimenez-Del-Rio M, Velez-Pardo C. Knockdown transgenic Lrrk Drosophila resists paraquat-induced locomotor impairment and neurodegeneration: A therapeutic strategy for Parkinson’s disease, Brain Res. 2016; 1657: 253-261. https://doi.org/10.1016/j.brainres.2016.12.023
Tapias V. Editorial: Mitochondrial Dysfunction and Neurodegeneration. Front Neurosci. 2019 Dec; 13 (1372): 1-4. https://doi.org/10.3389/fnins.2019.01372
Rzezniczak TZ, Douglas LA, Watterson JH, Merritt TJS. Paraquat administration in Drosophila for use in metabolic studies of oxidative stress. Anal Biochem. 2017; 419(2): 345–347. https://doi.org/10.1016/j.ab.2011.08.023
Stockum SV, Sanchez-Martinez A, Corra S. Inhibition of the deubiquitinase USP8 corrects a Drosophila PINK1 model of mitochondria dysfunction. Life sci alliance. 2019 Apr; 2(2): 1-16. https://doi.org/10.26508/lsa.201900392
McCann ME, de Graaff JC, Dorris L. Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial. Lancet. 2019 Feb; 393: 664–77. https://doi.org/10.1016/S0140-6736(18)32485-1
Nelson MP, Boutin M, Tonia ET, Lu H, Haley ED, Ouyang X, et al. The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson’s disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiol Dis . 2018 Feb; 110: 68–81. https://doi.org/10.1016/j.nbd.2017.11.006
Wells C, Brennan SE, Keon M, Saksena NK. Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases. Front. Mol. Neurosci. 2019 Nov; 12 (271): 1-24. https://doi.org/10.3389/fnmol.2019.00271
Lazzari FD, Sandrelli F, Whitworth AJ, Bisaglia M. Antioxidant Therapy in Parkinson’s Disease: Insights from Drosophila melanogaster. Antioxidants. 2020; 9 (52): 1-17. https://doi.org/10.3390/antiox9010052